PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-24.11%
G&A reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate efficiency gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-24.11%
Operating expenses reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
-24.11%
Total costs reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
10.43%
Interest expense change of 10.43% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify control.
No Data
No Data available this quarter, please select a different quarter.
24.11%
EBITDA change of 24.11% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
24.11%
Income change of 24.11% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
10.43%
Other expenses change of 10.43% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify control.
25.74%
Income change of 25.74% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
25.74%
Income change of 25.74% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
25.49%
EPS change of 25.49% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
25.49%
Diluted EPS change of 25.49% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.